Characteristics, n (%) | Total | Survivor | Non-Survivor | Mortality |
---|---|---|---|---|
n= | 73 | 37 | 36 | 49% |
female sex | 28 (38) | 18 (49) | 10 (28) | 26% |
male sex | 45 (62) | 19 (51) | 26 (72) | 58% |
age, years | 51 +/− 17 | 44 +/−15* | 57 +/− 16* | |
Body mass index, kg/m2 | 27.6 +/− 6.1 | 28.2 +/− 6.8 | 27.0 +/− 5.2 | |
SOFA score | 9 +/− 3 | 8 +/− 3† | 10 +/− 4† | |
immunocompromised status | 13 (18) | 2 (5) | 11 (31) | 85%‡ |
Immunocompetent status | 60 (82) | 35 (95) | 25 (69) | 42%‡ |
Origin of ARDS, n (%) | ||||
pneumonia | 44 (60) | 25 (68) | 19 (53) | 43% |
viral | 10 (14) | 7 (19) | 3 (8) | 30% |
bacterial | 29 (40) | 14 (38) | 15 (42) | 52% |
aspiration | 3 (4) | 3 (8) | 0 (0) | 0% |
trauma and burn | 10 (14) | 5 (14) | 5 (14) | 50% |
status asthmaticus | 3 (4) | 2 (5) | 1 (3) | 33% |
other | 16 (22) | 5 (14) | 11 (31) | 69% |
Severity of ARDS, n (%) | ||||
mild | 6 (8) | 4 (11) | 2 (6) | 33% |
moderate | 40 (55) | 20 (54) | 20 (56) | 50% |
severe | 27 (37) | 13 (35) | 14 (39) | 52% |
Ventilator/pECLA therapy | ||||
Duration of mechanical ventilation before pECLA, days | 8 +/− 8 | 6 +/− 7† | 10 +/− 10† | |
Duration of pECLA therapy, days | 8 +/− 8 | 7 +/− 5 | 9 +/− 9 | |
rescue therapy (ECMO) | 9 (12) | 5 (14) | 4 (11) | 44% |
no rescue therapy | 64 (78) | 32 (86) | 32 (89) | 50% |
Rescue therapy before pECLA | ||||
Inhaled nitric oxide | 11 (15) | 7 (19) | 4 (11) | 25% |
neuromuscular blockade agents | 0 (0) | 0 (0) | 0 (0) | |
prone position | 10 (14) | 4 (11) | 6 (17) | 60% |
Age, years, n (%) | ||||
18–49 | 31 (43) | 22 (59) | 9 (25) | 29%‡ |
50–59 | 14 (19) | 8 (22) | 6 (17) | 43%‡ |
≥ 60 | 28 (38) | 7 (19) | 21 (58) | 75%‡ |